Medtronic PLC (NYSE:MDT)‘s stock had its “buy” rating reaffirmed by Cowen and Company in a research note issued on Friday. They currently have a $95.00 price target on the medical technology company’s stock. Cowen and Company’s price target points to a potential upside of 21.03% from the company’s previous close.

Several other research analysts have also weighed in on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $89.00 target price (down from $92.00) on shares of Medtronic PLC in a research report on Tuesday, October 10th. Needham & Company LLC cut their target price on Medtronic PLC from $95.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, October 10th. Leerink Swann reaffirmed a “market perform” rating and issued a $85.00 target price (down from $88.00) on shares of Medtronic PLC in a research report on Monday, October 9th. Stifel Nicolaus cut their target price on Medtronic PLC from $91.00 to $83.00 and set a “hold” rating on the stock in a research report on Monday, October 9th. Finally, Royal Bank Of Canada cut their target price on Medtronic PLC from $90.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday, October 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $87.88.

Shares of Medtronic PLC (NYSE:MDT) traded down $1.82 during trading on Friday, hitting $78.50. The company’s stock had a trading volume of 4,294,043 shares, compared to its average volume of 5,979,703. The company has a market capitalization of $105.48 billion, a PE ratio of 16.60 and a beta of 1.00.

Medtronic PLC (NYSE:MDT) last issued its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.04. The business had revenue of $7.39 billion for the quarter, compared to analyst estimates of $7.44 billion. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the company posted $1.03 EPS. equities analysts expect that Medtronic PLC will post 4.64 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Medtronic PLC (MDT) Given Buy Rating at Cowen and Company” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/medtronic-plc-mdt-given-buy-rating-at-cowen-and-company.html.

In related news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic PLC stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $78.03, for a total value of $1,248,480.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Omar Ishrak sold 140,407 shares of Medtronic PLC stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the completion of the transaction, the chief executive officer now owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The disclosure for this sale can be found here. 0.31% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Hudock Capital Group LLC grew its stake in Medtronic PLC by 0.5% in the second quarter. Hudock Capital Group LLC now owns 2,195 shares of the medical technology company’s stock worth $194,000 after purchasing an additional 11 shares in the last quarter. Bollard Group LLC grew its stake in Medtronic PLC by 0.4% in the second quarter. Bollard Group LLC now owns 3,651 shares of the medical technology company’s stock worth $324,000 after purchasing an additional 14 shares in the last quarter. Triangle Securities Wealth Management grew its stake in Medtronic PLC by 0.3% in the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock worth $390,000 after purchasing an additional 15 shares in the last quarter. IFC Holdings Incorporated FL grew its stake in Medtronic PLC by 0.3% in the second quarter. IFC Holdings Incorporated FL now owns 5,673 shares of the medical technology company’s stock worth $501,000 after purchasing an additional 17 shares in the last quarter. Finally, North Star Investment Management Corp. grew its stake in Medtronic PLC by 1.1% in the second quarter. North Star Investment Management Corp. now owns 1,995 shares of the medical technology company’s stock worth $177,000 after purchasing an additional 22 shares in the last quarter. Institutional investors and hedge funds own 80.81% of the company’s stock.

Medtronic PLC Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Analyst Recommendations for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.